Simultaneous Dual Type 2 Biologic Therapy Improves Sinonasal Outcomes in Selected Patients With Chronic Rhinosinusitis With Nasal Polyps
Allergy · 2026-11 · 81 (11) · 3962-3971
DOI: 10.1111/all.70452 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Allergy, online erschienen am 04.08.2026. Verfasst von Friederike Bärhold und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Rhinology and Allergology, Wiesbaden, Germany. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Biological Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Background
Due to the shared underlying pathophysiological mechanism, chronic rhinosinusitis with nasal polyps (CRSwNP) is frequently associated with comorbid systemic type 2 diseases. Rare, complex cases treated simultaneously with two biologics due to inadequate disease control have been reported. The aim of this study was to assess current use of dual biologic therapy in patients with CRSwNP.
Methods
This retrospective, multicentric study included adult patients with a diagnosis of severe uncontrolled CRSwNP and simultaneous dual type‐2 biologic therapy, one of which had to be approved for the treatment of CRSwNP. Indication for dual therapy was made on an individual basis after interdisciplinary consultation.
Results
Thirty‐four patients diagnosed with CRSwNP from six study centers in Germany, the Netherlands, and Italy were included (mean age 49.1, 55.9% female). Most patients showed complex medical histories with type 2 comorbidities and several futile treatment attempts. The combination therapy consisted of dupilumab/mepolizumab ( n = 14), mepolizumab/tezepelumab ( n = 2), or benralizumab/dupilumab ( n = 14), dupilumab/omalizumab ( n = 3), or dupilumab/tezepelumab ( n = 1), with a median follow‐up time of 25 months (IQR = 6–34). Most frequent comorbidities were asthma ( n = 32), eosinophilic granulomatous polyangiitis ( n = 13), and hypereosinophilic syndrome ( n = 5). CRSwNP disease outcomes significantly improved under dual therapy at 6 months compared to baseline under single biologic therapy (SNOT22: −32.8, p < 0.0001; NPS: −3.2, p < 0.0001; Smell: +3.4, p = 0.003; VAS overall disease severity: −4.3, p = 0.054). Cessation of dual therapy was attempted in four patients, but reintroduced again due to loss of disease control. Five adverse reactions were reported in 4 (11.8%) patients: urticaria, erythema, gastrointestinal symptoms, weight gain, and arthralgia (each n = 1).
Conclusions
In rare cases, dual biologic therapy can be indicated to control CRSwNP and comorbid type 2 diseases. The long‐term efficacy and safety of this approach remain unknown and should be reserved for carefully selected cases only, considering the off‐label use in some European countries and high associated costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Rhinology and Allergology, Wiesbaden, Germany.
- Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli Universitary Hospital Foundation, IRCSS, Rome, Italy.
- Section of Otorhinolaryngology, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
- Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Munich, Germany.
- Department of Otorhinolaryngology, CCM and CVK, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Friederike Bärhold, Jan Hagemann, Eugenio de Corso, Anna Sophie Hoffmann, Patrick Huber, Moritz Gröger, Ulrike Förster-Ruhrmann, Sietze Reitsma, Ludger Klimek
Zitieren
APA
Bärhold, F., Hagemann, J., de Corso, E., Hoffmann, A. S., Zhu, F., Huber, P., Gröger, M., Förster-Ruhrmann, U., Reitsma, S., & Klimek, L. (2026). Simultaneous Dual Type 2 Biologic Therapy Improves Sinonasal Outcomes in Selected Patients With Chronic Rhinosinusitis With Nasal Polyps. Allergy, 81(11), 3962-3971. https://doi.org/10.1111/all.70452
Vancouver
Bärhold F, Hagemann J, de Corso E, Hoffmann AS, Zhu F, Huber P, et al. Simultaneous Dual Type 2 Biologic Therapy Improves Sinonasal Outcomes in Selected Patients With Chronic Rhinosinusitis With Nasal Polyps. Allergy. 2026;81(11):3962-3971. doi:10.1111/all.70452
BibTeX
@article{Brhold2026,
author = {Bärhold, Friederike and Hagemann, Jan and de Corso, Eugenio and Hoffmann, Anna Sophie and Zhu, Feifei and Huber, Patrick and Gröger, Moritz and Förster-Ruhrmann, Ulrike and Reitsma, Sietze and Klimek, Ludger},
title = {Simultaneous Dual Type 2 Biologic Therapy Improves Sinonasal Outcomes in Selected Patients With Chronic Rhinosinusitis With Nasal Polyps},
journal = {Allergy},
year = {2026},
volume = {81},
number = {11},
pages = {3962--3971},
doi = {10.1111/all.70452}
}
EUVIMED